Puro Risk Insights Blog
Our blog is an educational hub for clear and timely insights on the cannabis and hemp industry.
We simplify insurance topics regulatory updates and real world risks into easy to understand content for operators at every stage.
From cultivation to retail we provide practical guidance coverage education and market insights to help you stay compliant protected and informed so you can make smarter and more confident decisions.
ON THE BLOG
CATEGORIES
FEATURED POST
Recent Industry Updates
All Articles
Browse our complete collection of cannabis and hemp insights below. This page brings together all published articles covering policy and regulation, business and economy, legal and justice, industry innovation, and culture and community. Each post is created to educate and inform operators and industry stakeholders by breaking down complex topics into clear, practical insights. Scroll down to explore the full library and stay informed on the issues shaping the industry.
Federal CBD rules are finally on the table and the hemp market will feel it
A bipartisan House proposal would bring federal FDA rules to CBD and certain hemp derived products, replacing today’s patchwork. Here is what it means for labeling, testing, distribution, and competition with licensed cannabis.
Mature cannabis markets can still get dragged into rollback fights
A Massachusetts commission dismissed a challenge to an adult use cannabis repeal ballot effort, keeping the initiative moving forward procedurally. It’s a reminder that local policy risk can still impact valuations, retail footprints, and long term planning even in mature markets.
Legalization is changing who buys cannabis and operators need to notice
New research suggests legalization is expanding legal cannabis demand by drawing in more women and older adults. For operators, that means product formats, dosing clarity, and education first retail matter more than ever.
Cannabis genetics are turning into the next real power move
Aurora secured EU plant variety rights for two proprietary cannabis cultivars, signaling a bigger shift in the market. Protected genetics and consistent outputs are becoming the competitive moat as global medical cannabis matures.
When cannabis research gets delayed, the whole market stays “almost” legitimate
Federal delays in Schedule I research reforms are more than paperwork. They slow cannabis medical legitimacy, dosing standards, and the confidence insurers and mainstream capital need to support the market long term.
Federal seizures can still hit state legal cannabis operators
Federal seizures can still impact licensed cannabis businesses, even when they follow state rules. Here is why it happens, where operators get exposed, and how to reduce federal friction before it turns into inventory loss.
Cannabis M&A is not gone. It just went quiet.
Cannabis M&A is still happening, just quieter and more disciplined. Here is why deals moved behind closed doors, what buyers are targeting, and how operators can stay deal ready without getting crushed on terms.
A court ruling that quietly reshapes cannabis market access
A recent court decision strengthened cannabis residency requirements in key markets, reshaping who can participate and how deals get structured. Here is what operators need to know to protect market access, partnerships, and expansion plans.
Why Enforcement and Civil Rights Still Shape Cannabis Today
Cannabis is growing, but enforcement history and civil rights narratives still shape regulation, local politics, and business risk. Understanding that context helps operators build stability, trust, and long term resilience.
Canada’s Cannabis Market Signals What Comes Next for North America
Canada’s cannabis market continues to provide clear signals through wholesale trade data and measured retail expansion. These trends reflect a mature market that offers valuable lessons for North American operators.
Disclaimer: All content on this site is for informational and educational purposes only. We share news, insights, and our own interpretations but do not claim ownership of third-party content, always crediting original sources with links. Views expressed in shared content do not necessarily reflect our own. For accurate and current information, please consult the original publisher.
Ready to review your cannabis coverage?
Call us on (323)905-3396
or growth@cannashield.io

Trulieve and Cronos have each gained roughly 27 percent in 2026 while reporting stronger operating results. The broader signal is that public market attention is increasingly rewarding cash generation, improving margins, liquidity, and measurable revenue growth.